All In Biotech

Drug Trial Radar · NCT03681184

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

39

Actual

Start

Nov 27, 2018

Primary completion

Nov 5, 2019

Study completion Jan 12, 2024

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Sep 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).

Conditions

  • Primary Hyperoxaluria Type 1 (PH1)

Interventions

  • PlaceboDrug

    Placebo by SC injection

  • LumasiranDrug

    Lumasiran by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6Time frame: Baseline to Month 6

Locations

17 sites in 8 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    San Diego, California

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Lyon, France

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Haifa, Israel

  • Clinical Trial Site

    Jerusalem, Israel

  • Clinical Trial Site

    Nahariya, Israel

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    Bern, Switzerland

  • Clinical Trial Site

    Dubai, United Arab Emirates

  • Clinical Trial Site

    Birmingham, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.